Product Information
RISPERIDONE ER 50 MG VIAL is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $764.8189 per EA under NDC 00480145308. Its NADAC has been published 123 times since Apr 17, 2024.
FDA first approved this application on Dec 5, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Risperidone market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00480145308
Classification
Generic
Dosage Form
KIT
Effective Date
8/19/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA214068FDA Approved
12/5/2023
TE Code
AB
On Market Since
12/11/2023
Price Statistics
The NADAC for RISPERIDONE ER 50 MG VIAL has been published 123 times since Apr 17, 2024, and over the history we have for it it has declined 22.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $764.8189 per EA |
|---|---|
| All-time high | $989.6980 (May 15, 2024) |
| All-time low | $764.8189 (Aug 19, 2026) |
| 52-week high | $948.7572 |
| 52-week low | $764.8189 |
| Median price | $951.7423 |
| Average price | $939.7997 |
| Largest weekly change | -6.2% (Jun 17, 2026) |
| Weeks tracked | 123 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 54% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of RISPERIDONE ER 50 MG VIAL?
The current National Average Drug Acquisition Cost (NADAC) for RISPERIDONE ER 50 MG VIAL, manufactured by Teva Pharmaceuticals USA Inc., is $764.8189 per EA (NDC 00480145308), effective Aug 19, 2026.
How has the price of RISPERIDONE ER 50 MG VIAL changed over time?
Over the history we have for it, the NADAC for RISPERIDONE ER 50 MG VIAL has declined 22.7%. It has been tracked across 123 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for RISPERIDONE ER 50 MG VIAL?
Since Apr 17, 2024, the NADAC for RISPERIDONE ER 50 MG VIAL has ranged from a low of $764.8189 (Aug 19, 2026) to a high of $989.6980 (May 15, 2024), with a median of $951.7423 per EA.
Are there cheaper alternatives to RISPERIDONE ER 50 MG VIAL?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RISPERIDONE ER 25 MG VIAL, is $353.4887 per EA — about 54% below RISPERIDONE ER 50 MG VIAL.
Who manufactures RISPERIDONE ER 50 MG VIAL?
RISPERIDONE ER 50 MG VIAL (NDC 00480145308) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.